Nexalis Therapeutics Limited

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

inhalerx.com.au

Country

Australia

Exchange

ASX

Nexalis Therapeutics Limited, a biotechnology company develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression.

Formerly known as InhaleRx Limited, the company rebranded as Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.

Key Stats

52-Week Range

A$0.01A$0.04

Beta0.17

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.01

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.